On this Daily Dive episode, Cassandra talks to Dr. Sina Habibi, CEO of Cognetivity Neurosciences (CSE: CGN). He joins us to discuss the value of artificial intelligence and cognitive function tests in early detection of neurological issues (1:28). He also shares an update on his company’s FDA clearance (3:08), the new wellness app Optimind (5:09), and his thoughts on making Alzheimer’s a global health priority (9:46).
Cognetivity is a tech firm that has developed a cognitive testing platform for use in medical, commercial, and consumer environments. Through the use of AI and machine learning, the tech is able to detect the early onset of Alzheimer’s and dementia through testing the performance of large areas of the brain. The tech has acquired regulatory approval for use in both the UK and Europe, with further approvals in North America anticipated to occur.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. We may buy or sell securities in the company at any time. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
